Rigerna Therapeutics
PrivateLast Round
Early Funding
Apr 2, 2026
Total Funding Raised
$60M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Rigerna Therapeutics is a biotechnology company that develops nucleic acid drugs and siRNA therapies intended to treat liver and non-liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rigerna Therapeutics Comparables
Compare Rigerna Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rona Therapeutics | 88% | |
| Borealis Biosciences | 84% | |
| Argo Biopharma | 83% | |
Rigerna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Apr 2, 2026 | ||||
| Seed | Oct 1, 2024 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
$30M raised in early funding.
- Oct 1, 2024
$30M round completed.
Rigerna Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Rigerna Therapeutics's valuation, stock price, and market status.